Post by
Smokey1958 on Aug 09, 2021 8:18am
1drop
While the key piece of the NR is obviously the increase in overall testing and thus revenues there is another upside. 1drop, the company producing the test kits has developed and is selling a test kit that also screens for influenza and RSV. As the flu season approaches it would be surprising that SCRN would not upgrade to this kit for the film productions they're dealing with. The continuing expansion of their testing reach only adds to this potential.
As others have stated covid continues to flourish as a pandemic and has yet to taper off to endemic status. As such testing looks to be a longterm proposition and thus provides SCRN, even within the niche it currently occupies, significant revenues for the foreseeable future. Its capacity to distinguish between various respiratory ailments would be a fantastic development both for ScreenPro and its clients.
GLTE!!!
Comment by
bohemian62 on Aug 09, 2021 8:41am
Indeed and the revenue generated by SCRN can be used for growth and acquisitions in the telehealth industry . I see sp at .15 -. 25 range by December or sooner . Exciting times ahead . GLTA .